Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer

被引：2
|
作者：
Gouda, M. A. [1 ]
Sherman, E. J. [2 ]
Gilcrease, G. W. [3 ]
Vaishampayan, U. N. [4 ]
Parikh, A. [5 ]
Feun, L. [6 ]
Kummar, S. [7 ]
Huang, H. [1 ]
Zhang, C. [8 ]
Severson, P. [8 ]
Inokuchi, K. [8 ]
Silverman, M. [8 ]
Bollag, G. [8 ]
Janku, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA
[4] Univ Michigan, Div Hematol Oncol, Michigan Med, Ann Arbor, MI 48109 USA
[5] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[6] Sylvester Comprehens Canc Ctr, Hematol Oncol, Miami, FL USA
[7] Stanford Univ, Med Oncol, Palo Alto, CA 94304 USA
[8] Plexxikon Inc, Berkeley, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.643
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529MO
引用
收藏
页码：S465 / S465
页数：1
相关论文
共 50 条
  • [21] Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
    Day, D.
    Starus, A.
    Lamik, A.
    Sieber, O.
    Begbie, S.
    Bonaventura, A.
    Rai, S.
    Karanth, N.
    Underhill, C. R.
    Nott, L. M.
    Van Hazel, G.
    Van Hagen, T.
    Wong, M.
    Saqib, A.
    Eastgate, M.
    Srivastav, R.
    Chia, J.
    Toh, H. C.
    Jones, F.
    Segelov, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S710 - S710
  • [22] Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience
    Uccello, M.
    Kushnir, M.
    Mak, G.
    Henriquez, C. Murias
    Abbosh, C.
    Papadatos-Pastos, D.
    Newsom-Davis, T.
    Ahmad, T.
    Swanton, C.
    Forster, M.
    Lanman, R.
    Faull, I.
    Arkenau, H-T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis
    O'Sullivan, Niall J.
    Temperley, Hugo C.
    Kyle, Eimear T.
    Sweeney, Kevin J.
    O'Neill, Maeve
    Gilham, Charles
    O'Sullivan, Jacintha
    O'Kane, Grainne
    Mehigan, Brian
    O'Toole, Sharon
    Larkin, John
    Gallagher, David
    Mccormick, Paul
    Kelly, Michael E.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2024, 39 (01)
  • [24] Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
    De La Fuente, Macarena Ines
    Ahnert, Jordi Rodon
    Yaeger, Rona
    Tsai, Frank Yung-Chin
    Janku, Filip
    Butowski, Nicholas A.
    Allen, Carl E.
    Ammakkanavar, Natraj Reddy
    Taylor, Jennie Webster
    Michelson, Glenn
    Kline, Irina
    Paz, Michael
    Tussay-Lindenberg, Alexia
    Wong, Kongming
    Shepherd, Stacie Peacock
    Jiang, Ping
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] CIRCULATING TUMOUR DNA (ctDNA) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): PROGNOSTIC SIGNIFICANCE AND EARLY CHANGES DURING CHEMOTHERAPY
    Tie, J.
    Kinde, I.
    Wong, H. -L.
    McKendrick, J.
    Singh, M.
    Karapetis, C.
    Desai, J.
    Tran, B.
    Roebert, J.
    Kinzler, K.
    Vogelstein, B.
    Gibbs, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 50 - 50
  • [26] Cambridge liquid biopsy "CALIBRATION" study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
    Linossi, C.
    Williams, A.
    Baird, R.
    Dovedi, S.
    Fitzgerald, R.
    Pacey, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
    Clifton, Katherine
    Luo, Jingqin
    Tao, Yu
    Saam, Jennifer
    Rich, Thereasa A.
    Roshal, Anna
    Frith, Ashley Elizabeth
    Rigden, Caron E.
    Ademuyiwa, Foluso Olabisi
    Weilbaecher, Katherine N.
    Hernandez-Aya, Leonel Fernando
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Suresh, Rama
    Opyrchal, Mateusz
    Bose, Ron
    Wildes, Tanya Marya
    Ma, Cynthia X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)
    Clifton, Katherine
    Luo, Jingqin
    Tao, Yu
    Saam, Jennifer
    Rich, Thereasa
    Roshal, Anna
    Frith, Ashley
    Rigden, Caron
    Ademuyiwa, Foluso
    Weilbaecher, Katherine
    Hernandez-Aya, Leonel
    Peterson, Lindsay L.
    Bagegni, Nusayba
    Suresh, Rama
    Bose, Ron
    Opyrchal, Mateusz
    Wildes, Tanya M.
    Ma, Cynthia
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 639 - 646
  • [29] Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)
    Katherine Clifton
    Jingqin Luo
    Yu Tao
    Jennifer Saam
    Thereasa Rich
    Anna Roshal
    Ashley Frith
    Caron Rigden
    Foluso Ademuyiwa
    Katherine Weilbaecher
    Leonel Hernandez-Aya
    Lindsay L. Peterson
    Nusayba Bagegni
    Rama Suresh
    Ron Bose
    Mateusz Opyrchal
    Tanya M. Wildes
    Cynthia Ma
    Breast Cancer Research and Treatment, 2021, 185 : 639 - 646
  • [30] Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)
    Kushnir, M.
    Winter, H.
    Murias, C.
    Bains, P.
    Abbosh, C. Z.
    Papadatos-Pastos, D.
    Newsome-Davis, T.
    Ahmed, T.
    Swanton, C.
    Forster, M. D.
    Moore, D.
    Bennett, P.
    Faull, I.
    Lanman, R. B.
    Arkenau, H-T.
    ANNALS OF ONCOLOGY, 2018, 29
12345